Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) EPS (Basic) (2016 - 2025)

Coherus Oncology's EPS (Basic) history spans 13 years, with the latest figure at -$0.38 for Q4 2025.

  • For Q4 2025, EPS (Basic) rose 5.0% year-over-year to -$0.38; the TTM value through Dec 2025 reached -$1.56, down 603.23%, while the annual FY2025 figure was -$1.56, 17.02% up from the prior year.
  • EPS (Basic) for Q4 2025 was -$0.38 at Coherus Oncology, up from -$3.26 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $2.57 in Q2 2025 and bottomed at -$3.26 in Q3 2025.
  • The 5-year median for EPS (Basic) is -$0.49 (2021), against an average of -$0.57.
  • The largest YoY upside for EPS (Basic) was 2436.36% in 2025 against a maximum downside of 3522.22% in 2025.
  • A 5-year view of EPS (Basic) shows it stood at -$0.59 in 2021, then decreased by 28.81% to -$0.76 in 2022, then grew by 2.63% to -$0.74 in 2023, then skyrocketed by 45.95% to -$0.4 in 2024, then rose by 5.0% to -$0.38 in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EPS (Basic) are -$0.38 (Q4 2025), -$3.26 (Q3 2025), and $2.57 (Q2 2025).